<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82161">
  <stage>Registered</stage>
  <submitdate>20/07/2007</submitdate>
  <approvaldate>23/07/2007</approvaldate>
  <actrnumber>ACTRN12607000384459</actrnumber>
  <trial_identification>
    <studytitle>To evaluate the efficacy of nasal oxytocin in the treatment of migraine headaches</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate Nasal Oxytocin for the Treatment of Migraine Headaches</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>migraine headache</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>active drug: nasal oxytocin administered as one puff (100ÂµL, 4IU) in each nostril at time 0, 5 minutes, 10 minutes and 15 minutes on Study Day 1
</interventions>
    <comparator>control: placebo - saline nasal spray</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduction in headache intensity (5 Point Pain Intensity Scale)</outcome>
      <timepoint>2 hours after study drug administration</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction in headache intensity (5-Point Pain Intensity Scale) </outcome>
      <timepoint>At 0.5, 4 and 24 hours after study drug administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction in the following clinical signs and symptoms that may be associated with migraine </outcome>
      <timepoint>At 0.5, 2, 4 and 24 hours after study drug administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency/use of rescue medication </outcome>
      <timepoint>At 2, 4 and 24 hours after study drug administration.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall treatment satisfaction </outcome>
      <timepoint>24 hours after study drug administration.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of pain relief </outcome>
      <timepoint>After study drug administration.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosed with migraine according to IHS-criteria (see Appendix 1)Suffering from migraine &gt; 1 yearAt least 1-6 attacks per month in each of the six months prior to the start of this study Typical migraines of at least moderate intensity (based on a 5 point scale) if left untreatedAbility to reliably identify the onset of a migraine attackStarted suffering from migraine before age 50 years Female subjects of child-bearing potential who are fewer than 2 years post-menopausal, must agree to, and comply with, using highly effective methods of birth control (i.e. condom plus spermicide, combined oral contraceptive, implant, injectable, indwelling intrauterine device, sexual abstinence, or a vasectomized partner) while participating in this study.Written informed consent, willingness, and ability to comply with all study procedures</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Currently taking another investigational drug.Allergic to certain additives in the nasal oxytocin medication.Have other medical conditions that may interfere with participation in this study.Female and are pregnant or are nursing and will not agree to stop nursing.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Numbered containers</concealment>
    <sequence>Computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>site personnel, subjects, investigator and Sponsor will be blinded</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/09/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Trigemina, Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Trigemina, Inc.</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Trident Clinical Research</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Nasal oxytocin may be useful in preventing migraine attacks. The purpose of this study is to determine how well nasal oxytocin helps treat migraine attacks and the safety of nasal oxytocin and any side effects that may happen when it is given to migraine patients</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Investigator Clinic</ethicname>
      <ethicaddress>19 Oxford Terrace, Port Lincoln 5606 South Australia</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Trialworks</ethicname>
      <ethicaddress>Suites 4-5, Level 1, 14 Primrose Street, Sherwood Qld 4075</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Martin Angst</name>
      <address>Trigemina3 Inc.
809-B Cuesta Drive #109
Mountain View CA 94040</address>
      <phone>650 498 5109</phone>
      <fax />
      <email>ang@stanford.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Cathy Bradburn</name>
      <address>Trident Clinical Reseach
Suite 204
27 Merriwa Street
GORDON NSW 2072</address>
      <phone>02 9499 9996</phone>
      <fax />
      <email>cbradburn@tridentcr.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>